Swiss neurology specialist GeNeuro SA present first data linking silent COVID-19-induced inflammations to neuropsyciatric diseases.
Catalent has acquired a biologics manufacturing site from VMIC Ltd that is still under construction.
AXA IM Alts, has launched a Global Health Strategy following a €18m cornerstone commitment from AXA Group, as it builds on its existing offering in the sector.
German Bayer AG has announced it will channel at least €1.3b by the end of 2024 in its investment arm ‘Leaps by Bayer’.
Deep learning medical imaging specialist Qure.ai raises $40m from healthcare investors Novo Holdings and HealthQuad
Sanofi and IGM Biosciences have entered into a broad antibody discovery collaboration that could bring in IGM $6bn if all milestones are met.
XNK Therapeutics AB has secured a private placement of €12.75m led by Flerie Invest AB to finance Phase II development of CellProtect + Isatuximab in multiple myeloma.
CSL Behring has filed for accelerated approval of the first hemophilia B gene therapy in Europe.
Dutch autoimmunity specialist Argenx SE has raised $700m to prepare commercialisation of subcutanous efgartigimod as treatment for generalized myasthenia gravis.